Joseph J. Grudzinski, Ph.D.
Affiliations: | 2010 | University of Wisconsin, Madison, Madison, WI |
Area:
Oncology, Medical Biophysics, Radiation PhysicsGoogle:
"Joseph Grudzinski"Mean distance: (not calculated yet)
Parents
Sign in to add mentorRobert Jeraj | grad student | 2010 | UW Madison | |
(A whole-body pharmacokinetic model for the early assessment of targeted radionuclide therapy agents.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Adam DP, Grudzinski JJ, Marsh IR, et al. (2024) Voxel-level dosimetry for combined Iodine-131 radiopharmaceutical therapy and external beam radiotherapy treatment paradigms of head and neck cancer. International Journal of Radiation Oncology, Biology, Physics |
Adam DP, Hammer C, Malyshev JZ, et al. (2023) Creation of waterproof, TLD probes for dose measurements to validate image-based radiopharmaceutical therapy dosimetry workflow. Biomedical Physics & Engineering Express |
Marsh IR, Li C, Grudzinski J, et al. (2023) Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry. Cancer Biotherapy & Radiopharmaceuticals |
Kerr CP, Grudzinski JJ, Nguyen TP, et al. (2022) Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment. Pharmaceutics. 15 |
Potluri HK, Ferreira CA, Grudzinski J, et al. (2022) Antitumor efficacy of Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. Journal For Immunotherapy of Cancer. 10 |
Adam DP, Grudzinski J, Bormett I, et al. (2022) Validation of Monte Carlo I radiopharmaceutical dosimetry workflow using a 3D printed anthropomorphic head and neck phantom. Medical Physics |
Magee K, Marsh IR, Turek MM, et al. (2021) Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. Plos One. 16: e0255798 |
Patel RB, Hernandez R, Carlson P, et al. (2021) Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Science Translational Medicine. 13 |
Jagodinsky JC, Jin WJ, Bates AM, et al. (2021) Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 11: 6120-6137 |
Clark PA, Sriramaneni RN, Bates AM, et al. (2021) Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain. Radiation Research |